{"DataElement":{"publicId":"3444621","version":"1","preferredName":"Uterine Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for uterine carcinoma.","longName":"3444521v1.0:3444592v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3444521","version":"1","preferredName":"Corpus Uteri Neoplasm Stage Grouping","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"3444507v1.0:2230143v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3444507","version":"1","preferredName":"Corpus Uteri Neoplasm","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.:A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","longName":"C12316:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corpus Uteri","conceptCode":"C12316","definition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE75A97-CE75-0ED3-E040-BB89AD4366E2","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE75A97-CF5B-0ED3-E040-BB89AD4366E2","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3444592","version":"1","preferredName":"Corpus Uteri Carcinoma American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A term that refers to the staging of uterine corpus cancer according to the American Joint Committee on Cancer, 7th edition._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3444592v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9BC2-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444594","version":"1","preferredName":"Stage 0 Uterine Corpus Cancer","longName":"3444594","preferredDefinition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas.  FIGO no longer includes Stage 0 (Tis). (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Uterine Corpus Cancer AJCC v7","conceptCode":"C89632","definition":"Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas.  FIGO no longer includes Stage 0 (Tis). (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9BCF-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9BE8-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444596","version":"1","preferredName":"Stage I Uterine Corpus Cancer","longName":"3444596","preferredDefinition":"Stage I includes: I (T1, N0, M0); IA: (T1a, N0, M0); IB (T1b, N0, M0). T1: Tumor confined to corpus uteri. T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Uterine Corpus Cancer AJCC v7","conceptCode":"C89633","definition":"Stage I includes: I (T1, N0, M0); IA: (T1a, N0, M0); IB (T1b, N0, M0). T1: Tumor confined to corpus uteri. T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9BF5-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9C0E-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444598","version":"1","preferredName":"Stage IA Uterine Corpus Cancer","longName":"3444598","preferredDefinition":"Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Uterine Corpus Cancer AJCC v7","conceptCode":"C6301","definition":"Stage IA includes: T1a, N0, M0.  T1a: Tumor limited to the endometrium or invades less than one-half of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9C1B-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9C34-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444600","version":"1","preferredName":"Stage IB Uterine Corpus Cancer","longName":"3444600","preferredDefinition":"Stage IB includes: T1b, N0, M0.  T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Uterine Corpus Cancer AJCC v7","conceptCode":"C6302","definition":"Stage IB includes: T1b, N0, M0.  T1b: Tumor invades one-half or more of the myometrium. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9C41-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9C5A-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444602","version":"1","preferredName":"Stage II Uterine Corpus Cancer","longName":"3444602","preferredDefinition":"Stage II includes: T2, N0, M0.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Uterine Corpus Cancer AJCC v7","conceptCode":"C89634","definition":"Stage II includes: T2, N0, M0.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  Endocervical glandular involvement only should be considered as Stage I and not as Stage II.  N0: No regional lymph node metastasis. M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9C67-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9C80-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444604","version":"1","preferredName":"Stage III Uterine Corpus Cancer","longName":"3444604","preferredDefinition":"Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1-T3, N1/N2, M0); IIIC1 (T1-T3, N1, M0); IIIC2 (T1-T3, N2, M0). T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Uterine Corpus Cancer AJCC v7","conceptCode":"C89635","definition":"Stage III includes: III (T3, N0, M0); IIIA (T3a, N0, M0); IIIB (T3b, N0, M0); IIIC (T1-T3, N1/N2, M0); IIIC1 (T1-T3, N1, M0); IIIC2 (T1-T3, N2, M0). T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis to pelvic lymph nodes. N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9C8D-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9CA6-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444606","version":"1","preferredName":"Stage IIIA Uterine Corpus Cancer","longName":"3444606","preferredDefinition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Uterine Corpus Cancer AJCC v7","conceptCode":"C6306","definition":"Stage IIIA includes: T3a, N0, M0.  T3a: Tumor involves serosa and/or adnexa (direct extension or metastasis). N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9CB3-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9CCC-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444608","version":"1","preferredName":"Stage IIIB Uterine Corpus Cancer","longName":"3444608","preferredDefinition":"Stage IIIB includes: T3b, N0, M0.  T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Uterine Corpus Cancer AJCC v7","conceptCode":"C6307","definition":"Stage IIIB includes: T3b, N0, M0.  T3b: Tumor involves vagina (direct extension or metastasis) or parametrial tissue. N0: No regional lymph node metastasis. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9CD9-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9CF2-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IIIC1","valueDescription":"Stage IIIC1 Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444609","version":"1","preferredName":"Stage IIIC1 Uterine Corpus Cancer","longName":"3444609","preferredDefinition":"Stage IIIC1 includes: T1-T3, N1, M0.  T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. N1: Regional lymph node metastasis to pelvic lymph nodes. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC1 Uterine Corpus Cancer AJCC v7","conceptCode":"C95174","definition":"Stage IIIC1 includes: T1-T3, N1, M0.  T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue. N1: Regional lymph node metastasis to pelvic lymph nodes. M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9CFE-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9D17-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IIIC2","valueDescription":"Stage IIIC2 Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444610","version":"1","preferredName":"Stage IIIC2 Uterine Corpus Cancer","longName":"3444610","preferredDefinition":"Stage IIIC2 includes: T1-T3, N2, M0. T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue.  N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC2 Uterine Corpus Cancer AJCC v7","conceptCode":"C95176","definition":"Stage IIIC2 includes: T1-T3, N2, M0. T1: Tumor confined to corpus uteri.  T2: Tumor invades stromal connective tissue of the cervix but does not extend beyond uterus.  T3: Tumor involves serosa and/or adnexa, vagina, or parametrial tissue.  N2: Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes.  M0: No distant metastasis. This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9D23-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9D3C-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444612","version":"1","preferredName":"Stage IVA Uterine Corpus Cancer","longName":"3444612","preferredDefinition":"Stage IVA includes: T4, Any N, M0. T4: Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4).  M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Uterine Corpus Cancer AJCC v7","conceptCode":"C6309","definition":"Stage IVA includes: T4, Any N, M0. T4: Tumor invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4).  M0: No distant metastasis.  This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9D49-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9D62-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Uterine Corpus Cancer","ValueMeaning":{"publicId":"3444614","version":"1","preferredName":"Stage IVB Uterine Corpus Cancer","longName":"3444614","preferredDefinition":"Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Uterine Corpus Cancer AJCC v7","conceptCode":"C6310","definition":"Stage IVB includes: Any T, Any N, M1.  M1: Distant metastasis (includes metastasis to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone.  It excludes metastasis to para-aortic lymph nodes, vagina, pelvic serosa, or adnexa). This staging applies to carcinomas and carcinosarcomas. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9D6F-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BEE854C9-9D88-50CA-E040-BB89AD4341D5","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3444591","version":"1","preferredName":"Uterine Corpus Cancer by AJCC v7 Stage Stage Grouping Stage","preferredDefinition":"No Value Exists:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C91218:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Uterine Corpus Cancer by AJCC v7 Stage","conceptCode":"C91218","definition":"A term that refers to the staging of uterine corpus cancer (carcinoma or carcinosarcoma) according to the American Joint Committee on Cancer, 7th edition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9B99-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"ONEDATA","dateModified":"2012-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEE854C9-9BAA-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"COOPERM","dateModified":"2012-05-07","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3444894","version":"1","longName":"Corpus Uteri Carcinoma","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"5777530","version":"1","longName":"Uterine","context":"NCI Standards"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000689","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"BEE854C9-9EDE-50CA-E040-BB89AD4341D5","latestVersionIndicator":"Yes","beginDate":"2012-04-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-30","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}